Table: Daito -2024/25 parent results
Jul 11 (Reuters)-
Daito Pharamaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
May 31, 2025 May 31, 2024 May 31, 2026 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 50.44 46.59
(+8.3 pct) (+4.2 pct)
Operating 2.36 3.79
(-37.7 pct) (-24.6 pct)
Recurring 2.50 3.87
(-35.5 pct) (-23.8 pct)
Net 1.51 3.25
(-53.4 pct) (-6.9 pct)
EPS 49.74 yen 103.54 yen
Ann Div 70.00 yen 60.00 yen 40.00 yen
-Q2 Div 35.00 yen 30.00 yen 20.00 yen
-Q4 Div 35.00 yen 30.00 yen 20.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results